Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Logo de BioAtla aux formats PNG transparent et SVG vectorisé
BioAtla announces second quarter 2021 financial results - Medical Buyer
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M ...
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB ...
Bioatla Shares Surge on Strong Clinical and Financial Results - Stocks ...
BioAtla (BCAB.O) Plummets 15% Intraday—What’s Behind the Sudden Drop?
BioAtla Q2 2025 Earnings Call and Business Update Scheduled for August ...
BioAtla Virtual KOL Event - IASLC Data Review: BA3011 in Non-Small Cell ...
BioAtla Announces cPR for BA3182 at 0.6 mg in Phase 1 Study | BCAB ...
BioAtla Join Forces with Context Therapeutics to Develop and ...
BioAtla Secures FDA Alignment on Phase 3 Oz-V Cancer Drug Trial | BCAB ...
BioAtla Salaries | Levels.fyi
BioAtla (BCAB) Investor Presentation - Slideshow (NASDAQ:BCAB ...
BioAtla Shifts to 1-for-50 Merger Strategy After Nasdaq Blocks Reverse ...
BioAtla Secures $40M for Ozuriftamab Vedotin Phase 3 Trial | AIM Media ...
BioAtla Faces Financial Challenges Amid Promising Cancer Treatment ...
NEWS: BeiGene and BioAtla form worldwide collaboration to develop and ...
BioAtla (BCAB|$17.7M) - 2024 Q4 & Full Year Earnings Analysis - YouTube
Conditionally Active Biologics™ (CAB) - BioAtla
BioAtla (BCAB) sets $40M SPV to fund Phase 3 Oz-V OPSCC trial | BCAB ...
About Us | BioAtla
BioAtla (BCAB) Surges 24% on FDA Alignment and Strategic Milestones ...
BioAtla Announces First Patient Treated In Trial for CAB-AXL-ADC ...
BioAtla out-licenses T cell therapy in $134 million deal ...
BioAtla Advances Phase 3 Oz-V Programme with Manufacturing-Ready SPV ...
BioAtla Announces FDA Clearance of Investigational NDA for BA3011 ...
Video: BioAtla Stock Surges: FDA Greenlights Phase 3 Trial!
Conditionally Active Biologics™ (CAB) | BioAtla
BioAtla (BCAB) | Finance information
Last week BioAtla announced a licensing agreement with Context ...
BioAtla and GATC Health to advance Oz-V in Phase III trial
Clinical Trial Success Fuels BioAtla Stock Rally
BioAtla Says FDA Clears IND Application For BA3361 For The Treatment Of ...
BioAtla CEO and Key Executive Team | Craft.co
BioAtla (BCAB) Stock Price & Overview
BioAtla Virtual R&D Day: BA3071 CAB-CTLA-4 Phase 1 Data Review in ...
About Us - BioAtla
BioAtla 2026 Company Profile: Stock Performance & Earnings | PitchBook
IPO BioAtla Inc (BCAB)
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment ...
BioAtla Employee Perks & Benefits | Levels.fyi
Pfizer, BioAtla Sign Potential $1 Billion Biologics Deal - DCAT Value ...
BioAtla Presents Preliminary P-I Trial Data of BA3182 in Patients with ...
Bioatla (BCAB) up more than 100% since Aug 12
Buy BioAtla stock | $BCAB Share Price | Lightyear
BioAtla Enters into Agreements for up to $22.5 Million Flexible ...
BioAtla Careers | Levels.fyi
Bioatla Inc Stock Price ($BCAB), Quote & News | eToro
BioAtla and BeiGene Revise Global Development and Commercialization ...
IPO Alert: BioAtla (BCAB)
BioAtla Receives FDA Approval for BA3361 ADC - CTOL Digital Solutions
Bioatla Inc Stock Price Today | NASDAQ: BCAB Live - Investing.com
BioAtla gets FDA nod to start trials of BA3361, a CAB targeting Nectin ...
Bioatla 2025 Q3 Earnings Net Loss Widens 49% to $15.8M
Strategic Relationships | BioAtla
BioAtla and BeiGene Enter Collaboration to Develop BioAtla’s BA3071 ...
Bioatla Inc (BCAB) Stock Price & News - Google Finance
BioAtla and Pfizer in CAB antibody collaboration
BioAtla presents data of BA3182 for metastatic adenocarcinoma
BCAB - Bioatla Inc
Portfolio Companies past | HBM Partners
BioAtla_百度百科
BioAtla’s New Funding: A Double-Edged Sword for Shareholders
What Is BioAtla’s IPO Date and Price?
BioAtla's FDA Fast-Tracked Drug Boosts Its Oncology Prospects (NASDAQ ...
Exploring BioAtla, Inc. (BCAB): Who s Buying and Why? – DCFmodeling.com
Buy BioAtla, Inc Stock – BCAB Stock Quote Today & Investment Insights ...
BioAlta Yorkville
BioAtla, Inc. (BCAB): history, ownership, mission, how it works & makes ...
BioAtla’s AACR 2025 Breakthroughs: A New Frontier in Precision Oncology
Clinical trial using BioAtla's Conditionally Active Biologics for ...
BeiGene Enters $269 Million Agreement for BioAtla’s CTLA-4 Inhibitor ...
BioAtla's Big Reveal: What to Expect from Q4 2024 Earnings
BioAtla, GATC create $40M SPV: Oz‑V pushed into registrational Phase 3 ...
BioAtla, Inc. (NASDAQ:BCAB) Q3 2025 Earnings Call Transcript
Bioatla宣布CAB-AXL-ADC產品IND申請獲得FDA批准丨醫麥優企秀 - 每日頭條
Bioatla’s anti-Nectin-4 ADC gains IND clearance | BioWorld
BioAtla's (BCAB) Potential Gains Seen Despite Current Volatility.
Bioatla: The Most Undervalued Stock of 2025? - YouTube
BioAtla条件性pH激活抗 EpCAM x CD3 双特异性抗体设计 - 知乎
BioAtla’s Strategic Advancements and Promising Clinical Data Drive Buy ...
BioAtla, Inc. (BCAB) Stock Price, News, Quote & History - Yahoo Finance
Biotech Venture Capital | Highlights | Boxer Capital
开发创新抗癌疗法！BioAtla完成7250万美元D轮融资，百济神州已与其达成合作 - 知乎
国内首家！BioAtla申报靶向ROR2的ADC - 知乎
BCAB - Bioatla, Inc. Latest Stock News & Market Updates
Life Science Cares San Diego on LinkedIn: We are thrilled to announce ...
BioAtla’s Ozuriftamab Vedotin and Its Pathway to Accelerated Approval ...
Context builds up bank of bispecific antibodies with up to $133M ...
BCAB (BioAtla, Inc.) – Technical Charts and Market Data – TrendSpider
BioAtla's Innovative Cancer Biologics | PDF | Medicine | Causes Of Death
BioAtla, Inc. (BCAB) Latest Stock News & Headlines - Yahoo Finance
BCAB Stock | Bioatla, Inc. Price, Quote, News & Analysis - TipRanks.com
国外Biotech公司ADC产品技术特色
Bioatla's IND for bispecific antibody BA-3182 for adenocarcinoma ...
Do Insiders Own Lots Of Shares In BioAtla, Inc. (NASDAQ:BCAB)?
Testimonials - Scantech Graphics
